高效、紧凑且多功能：I-F2型CRISPR-Cas系统。 - Suppr

Suppr

超能文献

Efficient, compact, and versatile: Type I-F2 CRISPR-Cas system.

作者信息

Ma Shengsheng, Zhang Senfeng, Liu Kunming, Hu Tao, Hu Chunyi

机构信息

Department of Biological Sciences, Faculty of Science National University of Singapore Singapore Singapore.

Department of Biochemistry, Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore.

出版信息

mLife. 2024 Sep 22;3(3):384-386. doi: 10.1002/mlf2.12145. eCollection 2024 Sep.

DOI:10.1002/mlf2.12145

PMID:39359675

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11442125/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a95a/11442125/d9c2616b4e84/MLF2-3-384-g001.jpg

相似文献

Efficient, compact, and versatile: Type I-F2 CRISPR-Cas system.

mLife. 2024 Sep 22;3(3):384-386. doi: 10.1002/mlf2.12145. eCollection 2024 Sep.

analysis reveals the co-existence of CRISPR-Cas type I-F1 and type I-F2 systems and its association with restricted phage invasion in .

Front Microbiol. 2022 Aug 17;13:909886. doi: 10.3389/fmicb.2022.909886. eCollection 2022.

Genome and transcriptome engineering by compact and versatile CRISPR-Cas systems.

Drug Discov Today. 2023 Nov;28(11):103793. doi: 10.1016/j.drudis.2023.103793. Epub 2023 Oct 4.

Mechanistic insights into DNA binding and cleavage by a compact type I-F CRISPR-Cas system in bacteriophage.

Proc Natl Acad Sci U S A. 2023 May 2;120(18):e2215098120. doi: 10.1073/pnas.2215098120. Epub 2023 Apr 24.

Engineered minimal type I CRISPR-Cas system for transcriptional activation and base editing in human cells.

Nat Commun. 2024 Aug 23;15(1):7277. doi: 10.1038/s41467-024-51695-x.

Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing.

Mol Cell. 2021 Oct 21;81(20):4333-4345.e4. doi: 10.1016/j.molcel.2021.08.008. Epub 2021 Sep 3.

CRISPR beyond: harnessing compact RNA-guided endonucleases for enhanced genome editing.

Sci China Life Sci. 2024 Dec;67(12):2563-2574. doi: 10.1007/s11427-023-2566-8. Epub 2024 Jul 12.

Genomic and Phenotypic Analysis of Multidrug-Resistant Clinical Isolates Carrying Different Types of CRISPR/Cas Systems.

Pathogens. 2021 Feb 13;10(2):205. doi: 10.3390/pathogens10020205.

New CRISPR-Cas systems from uncultivated microbes.

Nature. 2017 Feb 9;542(7640):237-241. doi: 10.1038/nature21059. Epub 2016 Dec 22.

Endogenous Type I CRISPR-Cas: From Foreign DNA Defense to Prokaryotic Engineering.

Front Bioeng Biotechnol. 2020 Mar 4;8:62. doi: 10.3389/fbioe.2020.00062. eCollection 2020.

本文引用的文献

Engineered minimal type I CRISPR-Cas system for transcriptional activation and base editing in human cells.

Nat Commun. 2024 Aug 23;15(1):7277. doi: 10.1038/s41467-024-51695-x.

Versatile and efficient mammalian genome editing with Type I-C CRISPR System of Desulfovibrio vulgaris.

Sci China Life Sci. 2024 Nov;67(11):2471-2487. doi: 10.1007/s11427-023-2682-5. Epub 2024 Aug 7.

High-efficiency genome editing of an extreme thermophile using endogenous type I and type III CRISPR-Cas systems.

mLife. 2022 Dec 7;1(4):412-427. doi: 10.1002/mlf2.12045. eCollection 2022 Dec.

Reprogramming the endogenous type I CRISPR-Cas system for simultaneous gene regulation and editing in .

mLife. 2022 Mar 17;1(1):40-50. doi: 10.1002/mlf2.12010. eCollection 2022 Mar.

Structure and genome editing of type I-B CRISPR-Cas.

Nat Commun. 2024 May 15;15(1):4126. doi: 10.1038/s41467-024-48598-2.

Precise large-fragment deletions in mammalian cells and mice generated by dCas9-controlled CRISPR/Cas3.

Sci Adv. 2024 Mar 15;10(11):eadk8052. doi: 10.1126/sciadv.adk8052.

Exploiting activation and inactivation mechanisms in type I-C CRISPR-Cas3 for genome-editing applications.

Mol Cell. 2024 Feb 1;84(3):463-475.e5. doi: 10.1016/j.molcel.2023.12.034. Epub 2024 Jan 18.

Allosteric control of type I-A CRISPR-Cas3 complexes and establishment as effective nucleic acid detection and human genome editing tools.

Mol Cell. 2022 Aug 4;82(15):2754-2768.e5. doi: 10.1016/j.molcel.2022.06.007. Epub 2022 Jul 13.

Cas11 enables genome engineering in human cells with compact CRISPR-Cas3 systems.

Mol Cell. 2022 Feb 17;82(4):852-867.e5. doi: 10.1016/j.molcel.2021.12.032. Epub 2022 Jan 19.

Genome editing in mammalian cells using the CRISPR type I-D nuclease.

Nucleic Acids Res. 2021 Jun 21;49(11):6347-6363. doi: 10.1093/nar/gkab348.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Efficient, compact, and versatile: Type I-F2 CRISPR-Cas system.

作者信息

Ma Shengsheng, Zhang Senfeng, Liu Kunming, Hu Tao, Hu Chunyi

机构信息

Department of Biological Sciences, Faculty of Science National University of Singapore Singapore Singapore.

Department of Biochemistry, Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore.

出版信息

mLife. 2024 Sep 22;3(3):384-386. doi: 10.1002/mlf2.12145. eCollection 2024 Sep.

DOI:10.1002/mlf2.12145

PMID:39359675

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11442125/

Abstract

摘要

相似文献

Efficient, compact, and versatile: Type I-F2 CRISPR-Cas system.

mLife. 2024 Sep 22;3(3):384-386. doi: 10.1002/mlf2.12145. eCollection 2024 Sep.

analysis reveals the co-existence of CRISPR-Cas type I-F1 and type I-F2 systems and its association with restricted phage invasion in .

Front Microbiol. 2022 Aug 17;13:909886. doi: 10.3389/fmicb.2022.909886. eCollection 2022.

Genome and transcriptome engineering by compact and versatile CRISPR-Cas systems.

Drug Discov Today. 2023 Nov;28(11):103793. doi: 10.1016/j.drudis.2023.103793. Epub 2023 Oct 4.

Mechanistic insights into DNA binding and cleavage by a compact type I-F CRISPR-Cas system in bacteriophage.

Proc Natl Acad Sci U S A. 2023 May 2;120(18):e2215098120. doi: 10.1073/pnas.2215098120. Epub 2023 Apr 24.

Engineered minimal type I CRISPR-Cas system for transcriptional activation and base editing in human cells.

Nat Commun. 2024 Aug 23;15(1):7277. doi: 10.1038/s41467-024-51695-x.

Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing.

Mol Cell. 2021 Oct 21;81(20):4333-4345.e4. doi: 10.1016/j.molcel.2021.08.008. Epub 2021 Sep 3.

CRISPR beyond: harnessing compact RNA-guided endonucleases for enhanced genome editing.

Sci China Life Sci. 2024 Dec;67(12):2563-2574. doi: 10.1007/s11427-023-2566-8. Epub 2024 Jul 12.

Genomic and Phenotypic Analysis of Multidrug-Resistant Clinical Isolates Carrying Different Types of CRISPR/Cas Systems.

Pathogens. 2021 Feb 13;10(2):205. doi: 10.3390/pathogens10020205.

New CRISPR-Cas systems from uncultivated microbes.

Nature. 2017 Feb 9;542(7640):237-241. doi: 10.1038/nature21059. Epub 2016 Dec 22.

Endogenous Type I CRISPR-Cas: From Foreign DNA Defense to Prokaryotic Engineering.

Front Bioeng Biotechnol. 2020 Mar 4;8:62. doi: 10.3389/fbioe.2020.00062. eCollection 2020.

本文引用的文献

Engineered minimal type I CRISPR-Cas system for transcriptional activation and base editing in human cells.

Nat Commun. 2024 Aug 23;15(1):7277. doi: 10.1038/s41467-024-51695-x.

Versatile and efficient mammalian genome editing with Type I-C CRISPR System of Desulfovibrio vulgaris.

Sci China Life Sci. 2024 Nov;67(11):2471-2487. doi: 10.1007/s11427-023-2682-5. Epub 2024 Aug 7.

High-efficiency genome editing of an extreme thermophile using endogenous type I and type III CRISPR-Cas systems.

mLife. 2022 Dec 7;1(4):412-427. doi: 10.1002/mlf2.12045. eCollection 2022 Dec.

Reprogramming the endogenous type I CRISPR-Cas system for simultaneous gene regulation and editing in .

mLife. 2022 Mar 17;1(1):40-50. doi: 10.1002/mlf2.12010. eCollection 2022 Mar.

Structure and genome editing of type I-B CRISPR-Cas.

Nat Commun. 2024 May 15;15(1):4126. doi: 10.1038/s41467-024-48598-2.

Precise large-fragment deletions in mammalian cells and mice generated by dCas9-controlled CRISPR/Cas3.

Sci Adv. 2024 Mar 15;10(11):eadk8052. doi: 10.1126/sciadv.adk8052.

Exploiting activation and inactivation mechanisms in type I-C CRISPR-Cas3 for genome-editing applications.

Mol Cell. 2024 Feb 1;84(3):463-475.e5. doi: 10.1016/j.molcel.2023.12.034. Epub 2024 Jan 18.

Allosteric control of type I-A CRISPR-Cas3 complexes and establishment as effective nucleic acid detection and human genome editing tools.

Mol Cell. 2022 Aug 4;82(15):2754-2768.e5. doi: 10.1016/j.molcel.2022.06.007. Epub 2022 Jul 13.

Cas11 enables genome engineering in human cells with compact CRISPR-Cas3 systems.

Mol Cell. 2022 Feb 17;82(4):852-867.e5. doi: 10.1016/j.molcel.2021.12.032. Epub 2022 Jan 19.

Genome editing in mammalian cells using the CRISPR type I-D nuclease.

Nucleic Acids Res. 2021 Jun 21;49(11):6347-6363. doi: 10.1093/nar/gkab348.